L-DOPA-induced activation of striatal p38MAPK and CREB in neonatal dopaminergic denervated rat: Relevance to self-injurious behavior

Journal of Neuroscience Research

Volumn 86, Issue 2, 2008, Pages 339-349

  Sivam, Subbiah P ^a   Pugazhenthi, Subbiah ^b   Pugazhenthi, Vidya ^b   Brown, Heath ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE NORTHWEST   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

6 hydroxydopamine; CREB; Dopamine; L DOPA; p38MAPK; Self injurious behavior

Indexed keywords

LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOMUTILATION; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; OLFACTORY BULB; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANIMALS, NEWBORN; AXOTOMY; BLOTTING, WESTERN; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOPAMINE; DOPAMINE AGENTS; ENZYME ACTIVATION; LEVODOPA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SELF-INJURIOUS BEHAVIOR;

EID: 38849085904     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21504     Document Type: Article

References (102)

1. Arnauld E, Arsaut J, Demotes-Mainard J. 1998. Conditional coupling of striatal dopamine D1 receptor to transcription factors: ontogenic and regional differences in CPvEB activation. Brain Res Mol Brain Res 60:127-132.
2. Basura GJ, Walker PD. 1999. Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain up-regulated following suppression of serotonin hyperinnervation. Brain Res Dev Brain Res 116:111-117.
3. Berger TW, Kaul S, Stricker EM, Zigmond MJ. 1985. Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res 336:354-358.
4. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. 1998. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18:5301-5310.
5. Blake BL, Muehlmann AM, Egami K, Breese GR, Devine DP, Jinnah HA. 2007. Nifedipine suppresses self-injurious behaviors in animals. Dev Neurosci 29:241-250.
6. Breese GR, Traylor TD. 1972. Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine. Br J Pharmacol 44:210-222.
7. Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, Mueller RA. 1984a. Behavior differences between neonatal and adult 6-hydrocydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231:343-354.
8. Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Mueller RA. 1984b. Neonatal 6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Pharmacol Biochem Behav 21:459-461.
9. Breese GR, Napier TC, Mueller RA. 1985. Dopamine agonist induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D1 dopamine receptors in neonatally lesioned rats. J Pharmacol Exp Ther 234:447-455.
10. Breese GR, Mueller RA, Napier TC, Duncan GE. 1986. Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: relevance to Lesch-Nyhan disease. Adv Exp Med Biol 204:197-215.
11. Breese GR, Mueller RA, Napier CT, Duncan E. 1988. Neurobiology of D1 dopamine receptors after neonatal 6-OHDA treatment: relevance to Lesch-Nyhan disease. Adv Exp Med Biol 204:197-215.
12. Breese GR, Criswell HE, Johnson KB, O'Callaghan JP, Duncan GE, Jensen KF, Simson PE, Mueller RA. 1994. Neonatal destruction of dopaminergic neurons. Neurotoxicology 15:149-160.
13. Breese GR, Knapp DJ, Criswell HE, Moy SS, Papadeas ST, Blake BL. 2005. The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res Brain Res Rev 48:57-73.
14. Brown P, Gerfen CR. 2006. Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK1/2 map kinase pathway. J Comp Neurol 498:415-430.
15. Bruno JP, Zigmond MJ, Strieker EM. 1986. Rats given dopamine-depleting brain lesions as neonates do not respond to acute homeostatic imbalances as adults. Behav Neurosci 100:125-128.
16. Bruno JP, Jackson D, Zigmond MJ, Strieker EM. 1987. Effect of dopamine depleting brain lesions in rat pups: role of striatal serotonergic neurons in behavior. Behav Neurosci 101:806-811.
17. Byrnes EM, Ughrin Y, Bruno JP. 1996. Developmental plasticity in the D1- and D2-mediation of motor behavior in rats depleted of dopamine as neonates. Dev Psychobiol 29:653-666.
18. Calon F, Tahar AH, Blanchet PJ, Morissette M, Grondin R, Goulet M, Doucet JP, Robertson GS, Nestler E, Di Paolo T, Bedard PJ. 2000. Dopamine-receptor Stimulation: biobehavioral and biochemical consequences. Trend Neurosci 23(Suppl):S92-S101.
19. Carlezon WA Jr, Duman RS, Nesder EJ. 2005. The many faces of CREB. Trends Neurosci 28:436-445.
20. Cavanaugh JE, Jaumotte JD, Lakoski JM, Zigmond MJ. 2006. Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J Neurosci Res 84:1367-1375.
21. Chen J, Rusnak M, Luedtke RR, Sidhu A. 2004. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 279:39317-39330.
22. Chuderland D, Seger R. 2005. Protein-protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol 29:57-74.
23. Cole DG, Kobierski LA, Konradi C, Hyman SE. 1994. 6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element binding protein in striatal neurons. Proc Natl Acad Sci U S A 91:9631-9635.
24. Criswell H, Mueller RA, Breese GR. 1989. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA lesioned rats. J Neurosci 8:125-133.
25. Davies J, Tongroach P. 1978. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 51:91-100.
26. Dewar KM, Soghomonian JJ, Bruno JP, Descarries L, Reader TA. 1990. Elevation of dopamine D2 but not D1 receptors in adult rat neostriatum after neonatal 6-hydroxydopamine denervation. Brain Res 536:287-296.
27. Dragunow M. 2004. CREB and neurodegeneration. Front Biosci 9:100-103.
28. Duncan GE, Criswell HE, McCown TJ, Paul IA, Mueller RA, Breese GR. 1987. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. J Pharmacol Exp Ther 243:1027-1034.
29. Duncan GE, Breese GR, Criswell HE, Johnson KB, Schambra UB, Mueller RA, Caron MG, Fremeau JRT. 1993. D1 dopamine receptor binding and mRNA levels are not altered after neonatal 6-hydroxydopamine treatment: evidence against dopamine mediated induction of D12 dopamine receptors during postnatal development. J Neurochem 61:1255-1262.
30. Finkbeiner S. 2000. CREB couples neurotrophin signals to survival messages. Neuron 25:11-14.
31. Gerfen CR, Miyachi S, Paletzki R, Brown P. 2002. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22:5042-5054.
32. 3H-DOPA in various regions of the brain. J Neurochem 13:655-669.
33. Graybiel AM, Ragsdale CW Jr, Emson PC. 1983. Biochemical anatomy of the striatum. New York: Raven Press. p 427-504.
34. Graybiel AM, Moratalla R, Robertson HA. 1990. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci U S A 87:6912-6916.
35. Johnson BJ, Bruno JP. 1992. D-1 and D-2 receptor mediation of sensorimotor behavior in rats depleted of dopamine during development. Behav Brain Res 47:49-58.
36. Joyce JN, Frohna PA, Neal-Beliveau BS. 1996. Functional and molecular differentiation of the dopamine system induced by neonatal denervation. Neurosci Biobehav Rev 20:453-486.
37. Kebabian JW. 1993. Brain dopamine receptors: 20 years of progress. Neurochem Res 18:101-104.
38. Kies SD, Devine DP. 2004. Self-injurious behavior: a comparison of caffeine and pemoline models in rats. Pharmacol Biochem Behav 79:587-598.
39. Kim DS, Palmiter RD, Cummins A, Gerfen CR. 2006. Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 137:1381-1388.
40. King BH, Cromwell HC, Lee HT, Behrstock SP, Schmanke T, Maidment NT. 1998. Dopaminergic and glutamatergic interactions in the expression of self-injurious behavior. Dev Neurosci 20:180-187.
41. Kostrzewa RM, Reader TA, Descarries L. 1998. Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J Neurochem 70:889-898.
42. Lebel M, Robinson P, Cyr M. 2007. Canadian Association of Neurosciences Review: the role of dopamine receptor function in neurodegenerative diseases. Can J Neurol Sci 34:18-29.
43. Lesch M, Nyhan WL. 1964. A familial disorder of uric acid metabolism and central nervous system function. Am J Med 36:561-570.
44. Licata SC, Pierce RC. 2003. The roles of calcium/calmodulin-dependent and Ras/mitogen-activated protein kinases in the development of psychostimulant-induced behavioral sensitization. J Neurochem 85:14-22.
45. Liu FC, Graybiel AM. 1998a. Dopamine and calcium signal interactions in the developing striatum: control by kinetics of CREB phosphorylation. Adv Pharmacol 42:682-686.
46. Liu FC, Graybiel AM. 1998b. Region-dependent dynamics of cAMP response element-binding protein phosphorylation in the basal ganglia. Proc Natl Acad Sci U S A 95:4708-4713.
47. Lloyd KG, Hornykiewicz O, Davidson L, Shannak K, Farley I, Goldstein M, Shibuya H, Kelley WN, Fox IH. 1981. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 305:1106-1111.
48. Lonze BE, Ginty DD. 2002. Function and regulation of CREB family transcription factors in the nervous system. Neuron 35:605-623.
49. Luthman J, Bolioli B, Tsutsumi T, Verhofstad A, Jonsson G. 1987. Sprouting of striatal serotonin nerve terminal following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Res 19:269-274.
50. Luthman J, Lindqvist E, Young D, Cowburn R. 1990. Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity. Exp Brain Res 83:85-95.
51. Mabuchi T, Kitagawa K, Kuwabara K, Takasawa K, Ohtsuki T, Xia Z, Storm D, Yanagihara T, Hori M, Matsumoto M. 2001. Phosphorylation of cAMP response element-binding protein in hippocampal neurons as a protective response after exposure to glutamate in vitro and ischemia in vivo. J Neurosci 21:9204-9213.
52. Marshall CJ. 1995. Specificity of receptor tyrosine kinase signaling: transient vs. sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
53. Marshall JF, Navarrete R, Joyce JN. 1989. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Res 493:247-257.
54. Mattson MP. 2000. Apoptotic and anti-apoptotic synaptic signaling mechanisms. Brain Pathol 10:300-312.
55. Maudsley S, Martin B, Luttrell LM. 2005. The origins of diversity and specificity in g protein-coupled receptor signaling. J Pharmacol Exp Ther 314:485-494.
56. McDaid J, Graham MP, Napier TC. 2006. Methamphetamine-induced sensitization differentially alters pCREB and delta FosB throughout the limbic Circuit of the mammalian brain. Mol Pharmacol 70:2064-2074.
57. Meng SZ, Ozawa Y, Itoh M, Takashima S. 1999. Developmental and age-related changes of dopamine transporter and dopamine D1 and D2 receptors in human basal ganglia. Brain Res 843:136-144.
58. Meyer TE, Habener JF. 1993. Cyclic adenosine 3′,5′- monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocr Rev 14:269-290.
59. Nestler EJ. 2004. Molecular mechanisms of drug addiction. Neuropharmacology 47(Suppl 1):24-32.
60. Neve KA, Kozlowski MR, Marshall JF. 1982. Plasticity of neostriatal dopamine receptors after nigrostriatal injury: relationship to recovery of sensorimotor functions and behavioral supersensitivity. Brain Res 244:33-44.
61. Neve KA, Seamans JK, Trantham-Davidson H. 2004. Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205.
62. Okamura H, Murakami T, Yokoyama C, Nakamura T, Ibata Y. 1997. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine lesioned rat: 2. intracerebral microinjection of dopamine agonists and antagonists. J Pharmacol Expt Ther 280:1031-1037.
63. Onn SP, West AR, Grace AA. 2000. Dopamine-mediated regulation of striatal neuronal and network interactions. Trend Neurosci 23(Suppl):S48-S56.
64. Ono K, Han J. 2000. The p38 signal transduction pathway: activation and function. Cell Signal 12:1-13.
65. Papadeas ST, Blake BL, Knapp DJ, Breese GR. 2004. Sustained extracellular signal-regulated kinase 1/2 phosphorylation in neonate 6-hydroxydopamine- lesioned rats after repeated D1-dopamine receptor agonist administration: implications for NMDA receptor involvement. J Neurosci 24:5863-5876.
66. Paul A, Wilson S, Belham CM, Robinson CJ, Scott PH, Gould GW, Plevin R. 1997. Stress-activated protein kinases: activation, regulation and function. Cell Signal 9:403-410.
67. Pavon N, Martin AB, Mendialdua A, Moratalla R. 2006. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64-74.
68. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153-183.
69. Post GR, Brown JH. 1996. G protein-coupled receptors and signaling pathways regulating growth responses. FASEB J 10:741-749.
70. Pozzi L, Hakansson K, Usiello A, Borgkvist A, Lindskog M, Greengard P, Fisone G. 2003. Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem 86:451-459.
71. Pugazhenthi S, Phansalkar K, Audesirk G, West A, Cabell L. 2006. Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic Biol Med 40:21-34.
72. Robertson GS, Vincent SR, Fibiger HC. 1990. Striatonigral projection neurons contain D1 dopamine receptor- activated c-fos. Brain Res 523:288-290.
73. Rogue P, Malviya AN. 1994. Regulation of signalling pathways to the nucleus by dopaminergic receptors. Cell Signal 6:725-733.
74. Roux PP, Blenis J. 2004. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68:320-344.
75. Saito Y, Takashima S. 2000. Neurotransmitter changes in the pathophysiology of Lesch-Nyhan syndrome. Brain Dev 22(Suppl 1):S122-S131.
76. Schambra UB, Duncan GE, Breese GR, Fornaretto MG, Caron MG, Fremeau RT Jr. 1994. Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding. Neuroscience 62:65-85.
77. Schroeder SR, Oster-Granite ML, Berkson G, Bodfish JW, Breese GR, Cataldo MF, Cook EH, Crnic LS, DeLeon I, Fisher W, Harris JC, Horner RH, Iwata B, Jinnah HA, King BH, Lauder JM, Lewis MH, Newell K, Nyhan WL, Rojahn J, Sackett GP, Sandman C, Symons F, Tessel RE, Thompson T, Wong DF. 2001. Self-injurious behavior: gene-brain-behavior relationships. Ment Retard Dev Disabil Res Rev 7:3-12.
78. Sealfon SC, Olanow CW. 2000. Dopamine receptors: from structure to behavior. Trends Neurosci 23(Suppl):S34-S40.
79. Sivam SP. 1989. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: Implications for self-injurious behavior. Brain Res 500:119-130.
80. Sivam SP. 1995. Dopaminergic modulation of serotonin metabolism in rat striatum: a study with dopamine uptake inhibitor GBR-12909. Life Sci 56:PL467-PL472.
81. Sivam SP. 1996. Dopamine, serotonin and tachykinin in self-injurious behavior. Life Sci 58:2367-2375.
82. Sivam SP, Cox J. 2006. Postnatal administration of D1 dopamine agonist reverses neonatal dopaminergic lesion-induced changes in striatal enkephalin and substance P systems. Brain Res 1073-1074:159-163.
83. Sivam SP, Krause JE. 1990a. The adaptation of enkephalin, tachykinin and monoamine neurons of the basal ganglia following neonatal dopaminergic denervation is dependent on the extent of dopamine depletion. Brain Res 536:169-175.
84. Sivam SP, Krause JE. 1990b. Compensatory activation of substance P biosynthesis by L-dihydroxyphenylalanine in striatonigral neurons of neonatal dopaminergic denervated rats. J Pharmacol Exp Ther 254:433-439.
85. Sivam SP, Breese GR, Krause JE, Napier TC, Mueller RA, Hong JS. 1987. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression. J Neurochem 49:1623-1633.
86. Sivam SP, Krause JE, Breese GR, Hong JS. 1991. Dopamine-dependent postnatal development of enkephalin and tachykinin neurons of rat basal ganglia. J Neurochem 56:1499-1508.
87. Smith Y, Kieval JZ. 2000. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 23(Suppl):S28-S33.
88. Snyder AM, Zigmond MJ, Lund RD. 1986. Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J Comp Neurol 245:274-281.
89. Stachowiak MK, Bruno JP, Snyder AM, Stricker EM, Zigmond MJ. 1984. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res 291:164-167.
90. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. 2006. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 58:115-134.
91. Thomas GM, Huganir RL. 2004. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5:173-183.
92. Towle AC, Criswell HE, Maynard EH, Lauder JM, Joh TH, Mueller RA, Breese GR. 1989. Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: An anatomical, biochemical and pharmacological study. Pharmacol Biochem Behav 34:367-374.
93. Valjent E, Corvol JC, Pages C, Besson MJ, Maldonado R, Caboche J. 2000. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J Neurosci 20:8701-8709.
94. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC, Stipanovich A, Caboche J, Lombroso PJ, Nairn AC, Greengard P, Herve D, Girault JA. 2005. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A 102:491-496.
95. Winer BJ. 1983. Statistical principles in experimental design. New York: McGraw-Hill.
96. Wong DF, Harris JC, Naidu S, Yokoi F, Marenco S, Dannals RF, Ravert HT, Yaster M, Evans A, Rousset O, Bryan RN, Gjedde A, Kuhar MJ, Breese GR. 1996. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A 93:5539-5543.
97. Yadid G, Pacak K, Kopin IJ, Goldstein DS. 1994. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Ther 270:1158-1165.
98. Yokoyama C, Okamura H. 1997. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine lesioned rat: 1. Dopaminergic neurons and receptors. J Pharmacol Exp Ther 280:1016-1030.
99. Zawada WM, Meintzer MK, Rao P, Marotti J, Wang X, Esplen JE, Clarkson ED, Freed CR, Heidenreich KA. 2001. Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons. Brain Res 891:185-196.
100. Zhang L, Lou D, Jiao H, Zhang D, Wang X, Xia Y, Zhang J, Xu M. 2004. Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the dopamine D1 and D3 receptors. J Neurosci 24:3344-3354.
101. Zhen X, Uryu K, Wang HY, Friedman E. 1998. D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. Mol Pharmacol 54:453-458.
102. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Strieker EM. 1990. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications. Trends Neurosci 13:290-296.